The promise and challenges of stem cell-based therapies for skeletal diseases: Stem cell applications in skeletal medicine: Potential, cell sources and characteristics, and challenges of clinical translation

BioEssays

Volumn 35, Issue 3, 2013, Pages 220-230

  Diederichs, Solvig ^a   Shine, Kristy M ^a   Tuan, Rocky S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Mesenchymal stem cells; Orthopaedics; Pluripotent stem cells; Regenerative medicine; Skeletal repair

Indexed keywords

ARTICLE; BONE DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; MESENCHYME CELL; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION;

ANIMALS; BONE DISEASES; BONE MARROW CELLS; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; TISSUE ENGINEERING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84869478665     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201200068     Document Type: Article

References (99)

1. Noth U, Steinert AF, Tuan RS. 2008. Technology insight: adult mesenchymal stem cells for osteoarthritis therapy. Nat Clin Pract Rheumatol 4: 371-80.
2. Caplan AI. 2007. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213: 341-7.
3. Giannoudis PV, Einhorn TA, Marsh D. 2007. Fracture healing: the diamond concept. Injury 38: S3-6.
4. Peterson L, Minas T, Brittberg M, Nilsson A, et al. 2000. Two- to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin Orthop Relat Res 374: 212-34.
5. Stolzing A, Jones E, McGonagle D, Scutt A. 2008. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev 129: 163-73.
6. Bueno EM, Glowacki J. 2009. Cell-free and cell-based approaches for bone regeneration. Nat Rev Rheumatol 5: 685-97.
7. Farr J, Cole B, Dhawan A, Kercher J, et al. 2011. Clinical cartilage restoration: evolution and overview. Clin Orthop Relat Res 469: 2696-705.
8. Rodrigues MT, Reis RL, Gomes ME. 2012. Engineering tendon and ligament tissues: present developments towards successful clinical products. J Tissue Eng Regen Med, in press, DOI: 10.1002/term.1459.
9. Tanner KE. 2010. Bioactive composites for bone tissue engineering. Proc Inst Mech Eng H 224: 1359-72.
10. Friedlaender GE, Perry CR, Cole JD, Cook SD, et al. 2001. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83-A: S151-8.
11. Starman JS, Bosse MJ, Cates CA, Norton HJ. 2012. Recombinant human bone morphogenetic protein-2 use in the off-label treatment of nonunions and acute fractures: A retrospective review. J Trauma Acute Care Surg 72: 676-81.
12. Okubo Y, Bessho K, Fujimura K, Konishi Y, et al. 2000. Osteoinduction by recombinant human bone morphogenetic protein-2 at intramuscular, intermuscular, subcutaneous and intrafatty sites. Int J Oral Maxillofac Surg 29: 62-6.
13. Steadman JR, Rodkey WG, Briggs KK. 2002. Microfracture to treat full-thickness chondral defects: surgical technique, rehabilitation, and outcomes. J Knee Surg 15: 170-6.
14. Mithoefer K, McAdams T, Williams RJ, Kreuz PC, et al. 2009. Clinical efficacy of the microfracture technique for articular cartilage repair in the knee: an evidence-based systematic analysis. Am J Sports Med 37: 2053-63.
15. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, et al. 1994. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 331: 889-95.
16. Stokes DG, Liu G, Dharmavaram R, Hawkins D, et al. 2001. Regulation of type-II collagen gene expression during human chondrocyte de-differentiation and recovery of chondrocyte-specific phenotype in culture involves Sry-type high-mobility-group box (SOX) transcription factors. Biochem J 360: 461-70.
17. Christenson EM, Anseth KS, van den Beucken JJ, Chan CK, et al. 2007. Nanobiomaterial applications in orthopedics. J Orthop Res 25: 11-22.
18. Lee CH, Cook JL, Mendelson A, Moioli EK, et al. 2010. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. Lancet 376: 440-8.
19. Lau TT, Wang DA. 2011. Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther 11: 189-97.
20. Higashino K, Viggeswarapu M, Bargouti M, Liu H, et al. 2011. Stromal cell-derived factor-1 potentiates bone morphogenetic protein-2 induced bone formation. Tissue Eng Part A 17: 523-30.
21. Atala A, Bauer SB, Soker S, Yoo JJ, et al. 2006. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 367: 1241-6.
22. Caplan AI. 1991. Mesenchymal stem cells. J Orthop Res 9: 641-50.
23. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. 1968. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6: 230-47.
24. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, et al. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-7.
25. Caplan AI, Dennis JE. 2006. Mesenchymal stem cells as trophic mediators. J Cell Biochem 98: 1076-84.
26. Nauta AJ, Fibbe WE. 2007. Immunomodulatory properties of mesenchymal stromal cells. Blood 110: 3499-506.
27. da Silva Meirelles L, Caplan AI, Nardi NB. 2008. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 26: 2287-99.
28. Chatterjea A, Meijer G, van Blitterswijk C, de Boer J. 2010. Clinical application of human mesenchymal stromal cells for bone tissue engineering. Stem Cells Int 2010: 215625.
29. Murphy JM, Dixon K, Beck S, Fabian D, et al. 2002. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 46: 704-13.
30. De Bari C, Dell'Accio F, Karystinou A, Guillot PV, et al. 2008. A biomarker-based mathematical model to predict bone-forming potency of human synovial and periosteal mesenchymal stem cells. Arthritis Rheum 58: 240-50.
31. Dell'Accio F, De Bari C, Luyten FP. 2001. Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo. Arthritis Rheum 44: 1608-19.
32. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, et al. 2005. Spontaneous human adult stem cell transformation. Cancer Res 65: 3035-9.
33. Furlani D, Li W, Pittermann E, Klopsch C, et al. 2009. A transformed cell population derived from cultured mesenchymal stem cells has no functional effect after transplantation into the injured heart. Cell Transplant 18: 319-31.
34. Jeong JO, Han JW, Kim JM, Cho HJ, et al. 2011. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res 108: 1340-7.
35. Breitbach M, Bostani T, Roell W, Xia Y, et al. 2007. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110: 1362-9.
36. Pelttari K, Winter A, Steck E, Goetzke K, et al. 2006. Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. Arthritis Rheum 54: 3254-66.
37. Hellingman CA, Koevoet W, van Osch GJ. 2011. Can one generate stable hyaline cartilage from adult mesenchymal stem cells? A developmental approach. J Tissue Eng Regen Med, in press, DOI: 10.1002/term.502.
38. Hennig T, Lorenz H, Thiel A, Goetzke K, et al. 2007. Reduced chondrogenic potential of adipose tissue derived stromal cells correlates with an altered TGFbeta receptor and BMP profile and is overcome by BMP-6. J Cell Physiol 211: 682-91.
39. Jukes JM, Both SK, Leusink A, Sterk LM, et al. 2008. Endochondral bone tissue engineering using embryonic stem cells. Proc Natl Acad Sci USA 105: 6840-5.
40. Sensebe L, Bourin P, Tarte K. 2011. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther 22: 19-26.
41. Connolly JF, Guse R, Tiedeman J, Dehne R. 1991. Autologous marrow injection as a substitute for operative grafting of tibial nonunions. Clin Orthop Relat Res 259-70.
42. Hernigou P, Poignard A, Beaujean F, Rouard H. 2005. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 87: 1430-7.
43. Kasten P, Beyen I, Egermann M, Suda AJ, et al. 2008. Instant stem cell therapy: characterization and concentration of human mesenchymal stem cells in vitro. Eur Cell Mater 16: 47-55.
44. Muschler GF, Nitto H, Matsukura Y, Boehm C, et al. 2003. Spine fusion using cell matrix composites enriched in bone marrow-derived cells. Clin Orthop Relat Res 407: 102-18.
45. Sakai S, Mishima H, Ishii T, Akaogi H, et al. 2008. Concentration of bone marrow aspirate for osteogenic repair using simple centrifugal methods. Acta Orthop 79: 445-8.
46. Samuel GN, Kerridge IH, O'Brien TA. 2008. Umbilical cord blood banking: public good or private benefit? Med J Aust 188: 533-5.
47. 2011. Tooth cell service launched. Br Dent J 211: 452.
48. Ringden O, Uzunel M, Rasmusson I, Remberger M, et al. 2006. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81: 1390-7.
49. Niemeyer P, Kornacker M, Mehlhorn A, Seckinger A, et al. 2007. Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro. Tissue Eng 13: 111-21.
50. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, et al. 2003. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31: 890-6.
51. Huang XP, Sun Z, Miyagi Y, McDonald Kinkaid H, et al. 2010. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122: 2419-29.
52. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, et al. 2006. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108: 2114-20.
53. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, et al. 2001. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 344: 385-6.
54. Wakitani S, Imoto K, Yamamoto T, Saito M, et al. 2002. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage 10: 199-206.
55. Gómez-Barrena E, Rosset P, Muller I, Giordano R, et al. 2011. Bone regeneration: stem cell therapies and clinical studies in orthopaedics and traumatology. J Cell Mol Med 15: 1266-86.
56. Shenaq DS, Rastegar F, Petkovic D, Zhang BQ, et al. 2010. Mesenchymal progenitor cells and their orthopedic applications: forging a path towards clinical trials. Stem Cells Int 2010: 519028.
57. Zuk PA, Zhu M, Mizuno H, Huang J, et al. 2001. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7: 211-8.
58. Erices A, Conget P, Minguell JJ. 2000. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 109: 235-42.
59. Szpalski C, Barbaro M, Sagebin F, Warren SM. 2012. Bone tissue engineering: current strategies and techniques-part II: cell types. Tissue Eng Part B, Rev 18: 258-69.
60. Al-Nbaheen M, Vishnubalaji R, Ali D, Bouslimi A, et al. 2012. Human stromal (Mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev in press, DOI: 10.1007/s12015-012-9365-8.
61. Jeon K, Lim H, Kim JH, Thuan NV, et al. 2012. Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells Dev in press, DOI: 10.1089/scd.2011.0665.
62. Choi D, Oh HJ, Chang UJ, Koo SK, et al. 2002. In vivo differentiation of mouse embryonic stem cells into hepatocytes. Cell Transplant 11: 359-68.
63. Buhnemann C, Scholz A, Bernreuther C, Malik CY, et al. 2006. Neuronal differentiation of transplanted embryonic stem cell-derived precursors in stroke lesions of adult rats. Brain 129: 3238-48.
64. Wu SM, Hochedlinger K. 2011. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 13: 497-505.
65. Lister R, Pelizzola M, Kida YS, Hawkins RD, et al. 2011. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471: 68-73.
66. Gore A, Li Z, Fung H-L, Young JE, et al. 2011. Somatic coding mutations in human induced pluripotent stem cells. Nature 471: 63-7.
67. Zhao T, Zhang ZN, Rong Z, Xu Y. 2011. Immunogenicity of induced pluripotent stem cells. Nature 474: 212-5.
68. Cheng L, Hansen NF, Zhao L, Du Y, et al. 2012. Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression. Cell Stem Cell 10: 337-44.
69. Han DW, Tapia N, Hermann A, Hemmer K, et al. 2012. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 10: 465-72.
70. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, et al. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282: 1145-7.
71. Takahashi K, Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-76.
72. Wernig M, Zhao JP, Pruszak J, Hedlund E, et al. 2008. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 105: 5856-61.
73. Oki K, Tatarishvili J, Woods J, Koch P, et al. 2012. Human induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells 30: 1120-33.
74. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, et al. 2009. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation 120: 408-16.
75. Gamie Z, Tran GT, Vyzas G, Korres N, et al. 2012. Stem cells combined with bone graft substitutes in skeletal tissue engineering. Expert Opin Biol Ther 12: 713-29.
76. Arpornmaeklong P, Brown SE, Wang Z, Krebsbach PH. 2009. Phenotypic characterization, osteoblastic differentiation, and bone regeneration capacity of human embryonic stem cell-derived mesenchymal stem cells. Stem Cells Dev 18: 955-68.
77. Undale A, Fraser D, Hefferan T, Kopher RA, et al. 2011. Induction of fracture repair by mesenchymal cells derived from human embryonic stem cells or bone marrow. J Orthop Res 29: 1804-11.
78. Deyle DR, Khan IF, Ren G, Wang PR, et al. 2011. Normal collagen and bone production by gene-targeted human osteogenesis imperfecta iPSCs. Mol Ther 20: 204-13.
79. Medvedev SP, Grigor'eva EV, Shevchenko AI, Malakhova AA, et al. 2011. Human induced pluripotent stem cells derived from fetal neural stem cells successfully undergo directed differentiation into cartilage. Stem Cells Dev 20: 1099-112.
80. Hiramatsu K, Sasagawa S, Outani H, Nakagawa K, et al. 2011. Generation of hyaline cartilaginous tissue from mouse adult dermal fibroblast culture by defined factors. J Clin Invest 121: 640-57.
81. Barberi T, Willis LM, Socci ND, Studer L. 2005. Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med 2: e161.
82. Barbet R, Peiffer I, Hatzfeld A, Charbord P, et al. 2011. Comparison of gene expression in human embryonic stem cells, hESC-derived mesenchymal stem cells and human mesenchymal stem cells. Stem Cells Int 2011: 368192.
83. Trivedi P, Hematti P. 2008. Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol 36: 350-9.
84. Alper J. 2009. Geron gets green light for human trial of ES cell-derived product. Nat Biotechnol 27: 213-4.
85. Strauss S. 2010. Geron trial resumes, but standards for stem cell trials remain elusive. Nat Biotechnol 28: 989-90.
86. Frantz S. 2012. Embryonic stem cell pioneer Geron exits field, cuts losses. Nat Biotechnol 30: 12-3.
87. Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, et al. 2012. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 379: 713-20.
88. Arvidson K, Abdallah BM, Applegate LA, Baldini N, et al. 2011. Bone regeneration and stem cells. J Cell Mol Med 15: 718-46.
89. Dimitriou R, Jones E, McGonagle D, Giannoudis PV. 2011. Bone regeneration: current concepts and future directions. BMC Med 9: 66.
90. Jones E, Yang X. 2011. Mesenchymal stem cells and bone regeneration: current status. Injury 42: 562-8.
91. Fong EL, Chan CK, Goodman SB. 2011. Stem cell homing in musculoskeletal injury. Biomaterials 32: 395-409.
92. Aroen A. 2011. Stem cell therapy for articular cartilage defects. Br Med Bull 99: 227-40.
93. Sakai D. 2011. Stem cell regeneration of the intervertebral disk. Orthop Clin North Am 42: 555-62, viii-ix.
94. Young M. 2012. Stem cell applications in tendon disorders: a clinical perspective. Stem Cells Int 2012: 637836.
95. Isaac C, Gharaibeh B, Witt M, Wright VJ, et al. 2012. Biologic approaches to enhance rotator cuff healing after injury. J Shoulder Elbow Surg 21: 181-90.
96. Gulotta LV, Chaudhury S, Wiznia D. 2012. Stem cells for augmenting tendon repair. Stem Cells Int 2012: 291431.
97. Horie M, Driscoll MD, Sampson HW, Sekiya I, et al. 2012. Implantation of allogenic synovial stem cells promotes meniscal regeneration in a rabbit meniscal defect model. J Bone Joint Surg Am Volume 94: 701-12.
98. Gwathmey FW, Jr., Golish SR, Diduch DR. 2012. Complications in brief: meniscus repair. Clin Orthopa Relat Res 470: 2059-66.
99. Brophy RH, Matava MJ. 2012. Surgical options for meniscal replacement. J Am Acad Orthop Surg 20: 265-72.